Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer

We report herein the discovery and extensive characterization of ARD-1676, a highly potent and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was designed using a new class of AR ligands and a novel cereblon ligand. It has DC50 values of 0.1 and 1.1 nM in AR+ VCaP and LNC...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2023-09, Vol.66 (18), p.13280-13303
Main Authors: Xiang, Weiguo, Zhao, Lijie, Han, Xin, Xu, Tianfeng, Kregel, Steven, Wang, Mi, Miao, Bukeyan, Qin, Chong, Wang, Mingliang, McEachern, Donna, Lu, Jianfeng, Bai, Longchuan, Yang, Chao-Yie, Kirchhoff, Paul D., Takyi-Williams, John, Wang, Lu, Wen, Bo, Sun, Duxin, Ator, Mark, Mckean, Robert, Chinnaiyan, Arul M., Wang, Shaomeng
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report herein the discovery and extensive characterization of ARD-1676, a highly potent and orally efficacious PROTAC degrader of the androgen receptor (AR). ARD-1676 was designed using a new class of AR ligands and a novel cereblon ligand. It has DC50 values of 0.1 and 1.1 nM in AR+ VCaP and LNCaP cell lines, respectively, and IC50 values of 11.5 and 2.8 nM in VCaP and LNCaP cell lines, respectively. ARD-1676 effectively induces degradation of a broad panel of clinically relevant AR mutants. ARD-1676 has an oral bioavailability of 67, 44, 31, and 99% in mice, rats, dogs, and monkeys, respectively. Oral administration of ARD-1676 effectively reduces the level of AR protein in the VCaP tumor tissue in mice and inhibits tumor growth in the VCaP mouse xenograft tumor model without any sign of toxicity. ARD-1676 is a highly promising development candidate for the treatment of AR+ human prostate cancer.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.3c01264